All In Biotech

Drug Trial Radar · NCT05698329

Effect of AIV007 by Periocular Administration in Subjects With Macular Edema Secondary to nAMD and DME

A Phase 1 Study of the Safety, Pharmacokinetics, and Exploratory Efficacy of Periocular Administration of AIV007 in Subjects With Macular Edema Secondary to Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

19

Actual

Start

Mar 2, 2023

Primary completion

Mar 3, 2025

Study completion Mar 3, 2025

Sponsor

Lead sponsor
AiViva BioPharma, Inc.Industry
Sponsor type
Industry
First posted
Jan 26, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 21 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To determine safety, pharmacokinetics, and duration of effect of periocularly administered AIV007 gel suspension in subjects with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME).

Conditions

  • Neovascular Age-related Macular Degeneration
  • Diabetic Macular Edema
  • Macular Edema

Interventions

  • AIV007Drug

    Periocular injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse EventsTime frame: Approximately 168 days

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Retina-Vitreous Associates

    Beverly Hills, California

  • Orange County Retina

    Santa Ana, California

  • Verum Research

    Eugene, Oregon

  • Valley Retina Institute

    McAllen, Texas

  • Texas Retina Associates

    Plano, Texas

  • Medical Center Ophthalmology

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.